Drug intelligence / Profile preview

VIB193

Development stage: Preclinical
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intravenous

Overview

**VIB193** is a first-in-class T-cell engager (TCE) prodrug designed for the treatment of solid tumors. It specifically targets carbonic anhydrase IX (CAIX), a protein overexpressed on the surface of hypoxic tumor cells in various solid cancers, enabling selective activation and tumor-localized T-cell engagement to induce potent anti-tumor cytotoxicity while minimizing systemic toxicity. Developed as a prodrug to enhance safety and efficacy in the hypoxic tumor microenvironment, it represents a novel approach to immunotherapy for solid malignancies.

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on VIB193.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIB193.

Explore the full profile